Kodiak Sciences reports Q3 net loss of $61.5 million on $72 million cash balance

Reuters11-14

Kodiak Sciences reports Q3 net loss of $61.5 million on $72 million cash balance

Kodiak Sciences Inc. reported a net loss of $61.5 million, or $1.16 per share, for the third quarter of 2025, compared to a net loss of $43.9 million, or $0.84 per share, in the same quarter of 2024. Cash and cash equivalents at the end of the third quarter of 2025 were $72.0 million. The net loss for the third quarter of 2025 included a non-cash stock-based compensation expense of $14.0 million, compared to $14.8 million in the third quarter of 2024. During the period, Kodiak announced follow-up data from the Phase 1b APEX study of KSI-101 in macular edema secondary to inflammation, with more than half of patients achieving a vision improvement of three lines or more. The company is advancing Phase 3 programs for tarcocimab and KSI-501 in wet AMD and diabetic retinopathy, with key data readouts expected in 2026 and 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kodiak Sciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF24359) on November 13, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2583143195?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-14 05:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583143195","market":"nz","top_or_hot":-1,"title":"Kodiak Sciences reports Q3 net loss of $61.5 million on $72 million cash balance","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Kodiak Sciences reports Q3 net loss of $61.5 million on $72 million cash balance\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/KOD\">Kodiak Sciences Inc.</a> reported a net loss of $61.5 million, or $1.16 per share, for the third quarter of 2025, compared to a net loss of $43.9 million, or $0.84 per share, in the same quarter of 2024. Cash and cash equivalents at the end of the third quarter of 2025 were $72.0 million. The net loss for the third quarter of 2025 included a non-cash stock-based compensation expense of $14.0 million, compared to $14.8 million in the third quarter of 2024. During the period, Kodiak announced follow-up data from the Phase 1b APEX study of KSI-101 in macular edema secondary to inflammation, with more than half of patients achieving a vision improvement of three lines or more. The company is advancing Phase 3 programs for tarcocimab and KSI-501 in wet <a href=\"https://laohu8.com/S/AMD\">AMD</a> and diabetic retinopathy, with key data readouts expected in 2026 and 2027.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kodiak Sciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF24359) on November 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kodiak Sciences reports Q3 net loss of $61.5 million on $72 million cash balance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKodiak Sciences reports Q3 net loss of $61.5 million on $72 million cash balance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-14 05:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Kodiak Sciences reports Q3 net loss of $61.5 million on $72 million cash balance\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/KOD\">Kodiak Sciences Inc.</a> reported a net loss of $61.5 million, or $1.16 per share, for the third quarter of 2025, compared to a net loss of $43.9 million, or $0.84 per share, in the same quarter of 2024. Cash and cash equivalents at the end of the third quarter of 2025 were $72.0 million. The net loss for the third quarter of 2025 included a non-cash stock-based compensation expense of $14.0 million, compared to $14.8 million in the third quarter of 2024. During the period, Kodiak announced follow-up data from the Phase 1b APEX study of KSI-101 in macular edema secondary to inflammation, with more than half of patients achieving a vision improvement of three lines or more. The company is advancing Phase 3 programs for tarcocimab and KSI-501 in wet <a href=\"https://laohu8.com/S/AMD\">AMD</a> and diabetic retinopathy, with key data readouts expected in 2026 and 2027.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kodiak Sciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF24359) on November 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KOD","symbol_name":"Kodiak Sciences Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL4Gjryg:1","article_id":"2583143195","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583143195","pubTimestamp":1763068055,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Kodiak Sciences Inc. reported a net loss of $61.5 million, or $1.16 per share, for the third quarter of 2025, compared to a net loss of $43.9 million, or $0.84 per share, in the same quarter of 2024. Cash and cash equivalents at the end of the third quarter of 2025 were $72.0 million. The net loss for the third quarter of 2025 included a non-cash stock-based compensation expense of $14.0 million, compared to $14.8 million in the third quarter of 2024. During the period, Kodiak announced follow-up data from the Phase 1b APEX study of KSI-101 in macular edema secondary to inflammation, with more than half of patients achieving a vision improvement of three lines or more. The company is advancing Phase 3 programs for tarcocimab and KSI-501 in wet AMD and diabetic retinopathy, with key data readouts expected in 2026 and 2027.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KOD":"Kodiak Sciences Inc.","BK4139":"生物科技","BK4505":"高瓴资本持仓"},"translate_title":"Kodiak Sciences报告第三季度净亏损6150万美元，现金余额7200万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KOD":0.9},"content_text":"Kodiak Sciences reports Q3 net loss of $61.5 million on $72 million cash balance\n    \n\nKodiak Sciences Inc. reported a net loss of $61.5 million, or $1.16 per share, for the third quarter of 2025, compared to a net loss of $43.9 million, or $0.84 per share, in the same quarter of 2024. Cash and cash equivalents at the end of the third quarter of 2025 were $72.0 million. The net loss for the third quarter of 2025 included a non-cash stock-based compensation expense of $14.0 million, compared to $14.8 million in the third quarter of 2024. During the period, Kodiak announced follow-up data from the Phase 1b APEX study of KSI-101 in macular edema secondary to inflammation, with more than half of patients achieving a vision improvement of three lines or more. The company is advancing Phase 3 programs for tarcocimab and KSI-501 in wet AMD and diabetic retinopathy, with key data readouts expected in 2026 and 2027.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kodiak Sciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF24359) on November 13, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2583143195","isCrawlerRequest":true}